Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Systemic Mastocytosis With an Associated Hematologic Neoplasm”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Not applicableStudy completedNCT04695431
What this trial is testing

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Who this might be right for
Advanced Systemic MastocytosisAggressive Systemic MastocytosisSystemic Mastocytosis With an Associated Hematological Neoplasm+1 more
Blueprint Medicines Corporation 317
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Large-scale testing (Phase 3)Study completedNCT00666211
What this trial is testing

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more
Vanderbilt-Ingram Cancer Center 98
Testing effectiveness (Phase 2)WithdrawnNCT01101412
What this trial is testing

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Who this might be right for
Chronic Myeloproliferative DisordersInfectionLeukemia+6 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00782067
What this trial is testing

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Who this might be right for
Leukemia
Novartis Pharmaceuticals 116
Not applicableNo Longer AvailableNCT05219266
What this trial is testing

Managed Access Programs for PKC412, Midostaurin

Who this might be right for
FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid LeukemiaAcute Myeloid LeukemiaAggressive Systemic Mastocytosis+2 more
Novartis Pharmaceuticals
Not applicableAvailableNCT06915766
What this trial is testing

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Who this might be right for
Systemic Mastocytoses, IndolentSystemic Mastocytoses, Aggressive
Cogent Biosciences, Inc.
Early research (Phase 1)Looking for participantsNCT06327685
What this trial is testing

Avapritinib With Decitabine in Patients With SM-AHN

Who this might be right for
Systemic Mastocytosis With an Associated Hematologic Neoplasm
H. Lee Moffitt Cancer Center and Research Institute 34
Testing effectiveness (Phase 2)Study completedNCT01807598
What this trial is testing

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Who this might be right for
Aggressive Systemic MastocytosisMast Cell LeukemiaSystemic Mastocytosis
Jason Robert Gotlib 10
Testing effectiveness (Phase 2)Looking for participantsNCT04996875
What this trial is testing

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Who this might be right for
Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more
Cogent Biosciences, Inc. 140
Testing effectiveness (Phase 2)Study completedNCT03580655
What this trial is testing

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Who this might be right for
Advanced Systemic MastocytosisAggressive Systemic MastocytosisSystemic Mastocytosis With an Associated Hematologic Neoplasm+1 more
Blueprint Medicines Corporation 107